ImmunityBio, Inc. (IBRX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 26,425 | 16,517 | 6,106 | 1,047 |
| Selling, general and administrative | - | 32,654 | 35,916 | 49,251 |
| Research and development | - | 48,234 | 50,443 | 51,129 |
| Cost of sales | - | 58 | - | - |
| Total operating costs and expenses | - | 80,946 | - | - |
| Total operating costs and expenses | - | - | 86,359 | 100,380 |
| Loss from operations | -71,285 | -64,429 | -80,253 | -99,333 |
| Interest expense related to revenue interest liability | - | - | 10,925 | 9,225 |
| Interest expense (including amounts with related parties) | - | - | 29,322 | 29,794 |
| Other expense, net | - | -41 | 12 | -17 |
| Interest expense related to revenue interest liability | - | 13,534 | - | - |
| Interest expense (including amounts with related parties) | - | 15,331 | - | - |
| Interest and investment income, net | - | 887 | 1,798 | 1,891 |
| Change in fair value of related-party convertible note | - | -42,582 | - | - |
| Change in fair value of warrant liabilities | - | 448 | -31,324 | 19,300 |
| Change in fair value of derivative liabilities | - | 5,578 | 1,614 | 21,194 |
| Total other expense, net | - | -65,471 | -5,499 | -35,251 |
| Loss before income taxes and noncontrolling interests | -92,305 | -129,900 | -85,752 | -134,584 |
| Income tax expense | 269 | -234 | - | - |
| Net loss | -92,574 | -129,666 | -85,752 | -134,584 |
| Net loss attributable to noncontrolling interests, net of tax | -19 | -20 | -23 | -20 |
| Net loss attributable to immunitybio common stockholders | -92,555 | -129,646 | -85,729 | -134,564 |
| Net loss per immunitybio common share basic (in dollars per share) | -0.1 | -0.15 | -0.12 | -0.2 |
| Net loss per immunitybio common share - diluted (in dollars per share) | -0.1 | -0.15 | -0.14 | -0.2 |
| Weighted-average number of common shares used in computing net loss per share basic (in shares) | 888,216,000 | 853,162,000 | 695,895,000 | 686,938,120 |
| Weighted-average number of common shares used in computing net loss per share diluted (in shares) | 888,216,000 | 853,162,000 | 697,961,000 | 686,938,120 |